“Research in breast cancer has lately allowed to characterize molecular features that have increasingly become the targets for novel therapeutic interventions. …
source : http://www.sciencedaily.com/releases/2014/03/140324133244.htm
The findings, published in the journal Lancet Oncology, investigated the timing of trastuzumab administration with anthracycline and taxane chemotherapy. "In a previous MD Anderson study concurrent administration of trastuzumab with chemotherapy, including anthracyclines, demonstrated high pathologic complete response rates in breast cancer patients with HER-2-positive disease," Buzdar said. …